肌少症与夜尿症的独立相关性及与超重的协同致病效应研究

Correlation of sarcopenia with nocturia and the synergistic pathogenic interaction with overweight

摘要

目的 探讨肌少症、超重与夜尿症的相关性，以期为夜尿症的病因识别提供依据。方法 基于2011-2018年美国国家健康与营养调查（NHANES）数据库，纳入12 711名具有完整数据的参与者，其中肌少症患者1156例，夜尿症患者2911例。应用多因素logistic回归模型逐层校正混杂因素，分析肌少症与夜尿症的关联，并进行亚组及分层分析。结果 夜尿症组肌少症患病率高于无夜尿症组（13.0%对比7.9%，P＜0.001），多因素校正后，肌少症是夜尿症的独立危险因素（OR=1.592，95%CI:1.277～1.986，P＜0.001），超重人群合并肌少症时夜尿症风险进一步升高（OR=1.508，95%CI:1.178～1.930，P=0.002）。肌少症合并超重组夜尿症患病率高于有单纯超重或肌少症组（χ²=42.132，P＜0.001）。亚组分析显示，肌少症与夜尿症的关联存在人群异质性，在不同性别、全年龄段、非西班牙裔、高中以上学历、各类吸烟人群、少量饮酒及无基础慢性病人群中更为显著（P ＜0.05）。结论 肌少症是夜尿症的独立危险因素，肌少症合并超重人群夜尿患病风险进一步升高。

Abstract

Objective To investigate the independent association between sarcopenia, overweight and nocturia, so as to provide evidence-based insights for the etiology of nocturia. Methods Data from the 2011-2018 National Health and Nutrition Examination Survey (NHANES) were analyzed. A total of 12 711 participants with complete information were involved, including 1156 individuals with sarcopenia and 2911 with nocturia. Multivariable logistic regression models were used to assess the association between sarcopenia and nocturia with stepwise adjustment for potential confounding factors. Subgroup and stratified analyses were further performed to evaluate the consistency of the association across different populations. Results The prevalence of sarcopenia was significantly higher in participants with nocturia than in those without(13.0% vs. 7.9%, P＜0.001). After multivariable adjustment, sarcopenia remained independently associated with nocturia(OR=1.592, 95%CI:1.277-1.986, P＜0.001). Further analysis showed that overweight individuals with sarcopenia had an increased risk of nocturia(OR=1.508, 95%CI:1.178-1.930, P=0.002). Chi-square test revealed that the prevalence of nocturia was higher in participants with complicated sarcopenia and overweight than in those with only overweight or sarcopenia(χ2 = 42.132, P＜0.001). Subgroup analyses revealed population heterogeneity in the association between sarcopenia and nocturia, with a more pronounced association observed among different genders, age, non-Hispanic participants, individuals with high school education or above, various smoking participants, those with light alcohol consumption, and those without chronic diseases(P＜0.05). Conclusion Sarcopenia is an independent risk factor for nocturia. The coexistence of sarcopenia and overweight is associated with an increased risk of nocturia.

关键词

肌少症 / 夜尿症 / BMI / 超重

Key words

sarcopenia / nocturia / body mass index / overweight

参考文献

[1] WANG Y, HU H, XU K, et al. Prevalence, risk factors, and symptom bother of nocturia: a population-based survey in China[J]. World J Urol, 2015, 33(5): 677-683.

[2] BOSCH JLHR, WEISS JP. The prevalence and causes of nocturia[J]. J Urol, 2010, 184(2): 440-446.

[3] GETANEH FW, SUSSMAN RD, IGLESIA CB. Nocturia: evaluation and management[J]. Am Fam Physician, 2025, 111(6): 515-523.

[4] MOBLEY DF, BAUM N. Etiology, evaluation, and management of nocturia in elderly men and women[J]. Postgrad Med, 2014, 126(2): 147-153.

[5] 黄浩, 黄海, 陈沛贤. 新医改下的机遇与挑战:社区中的尿失禁防治工作如何开展[J]. 临床泌尿外科杂志, 2024, 39(2): 89-92.

[6] LI J, TU H, ZHANG Y, et al. Risks of all-cause mortality in adults with chronic kidney disease with sarcopenia or obesity: a population-based study[J]. J Cachexia Sarcopenia Muscle, 2025, 16(3): e13828.

[7] WEI JT, DAUW CA, BRODSKY CN. Lower urinary tract symptoms in men: a review[J]. JAMA, 2025, 334(9): 809-821.

[8] ZHANG F, LI W. Association of sarcopenia and urinary incontinence in adult women aged less than 60 years[J]. Int J Womens Health, 2025, 17: 695-709.

[9] SHAO F, LUO W, LOU L, et al. Associations of sarcopenia, obesity, and metabolic health with the risk of urinary incontinence in U.S. adult women: a population-based cross-sectional study[J]. Front Nutr, 2024, 11: 1459641.

[10] BURGIO KL, KRAUS SR, JOHNSON TMN, et al. Effectiveness of combined behavioral and drug therapy for overactive bladder symptoms in men: a randomized clinical trial[J]. JAMA Intern Med, 2020, 180(3): 411-419.

[11] JOHNSON TMN, BURGIO KL, REDDEN DT, et al. Effects of behavioral and drug therapy on nocturia in older incontinent women[J]. J Am Geriatr Soc, 2005, 53(5): 846-850.

[12] LIN W, HUANG H, OU Y, et al. Rising prevalence of urinary incontinence and nocturia amid the COVID-19 pandemic[J]. Neurourol Urodyn, 2025, 44(5): 1090-1098.

[13] ERDOGAN T, BAHAT G, KILIC C, et al. The relationship between sarcopenia and urinary incontinence[J]. Eur Geriatr Med, 2019, 10(6): 923-929.

[14] FU Z, WANG F, DANG X, et al. The association between diabetes and nocturia: a systematic review and meta-analysis[J]. Front Public Health, 2022, 10: 924488.

[15] TU D, SUN J, WANG P, et al. Overall sleep quality is associated with advanced stages in patients with cardiovascular-kidney-metabolic syndrome[J]. J Am Heart Assoc, 2025, 14(7): e38674.

[16] CAI Y, LIANG Y, HU X, et al. Inverse association between dietary flavonoid intake and nocturia in middle-aged and older adults from NHANES 2007-2010[J]. Sci Rep, 2025, 15(1): 4423.

[17] SHIGEHARA K, IZUMI K, MIZOKAMI A, et al. Testosterone deficiency and nocturia: a review[J]. World J Mens Health, 2017, 35(1): 14-21.

[18] ASLAN E, KOMURCU N, BEJI NK, et al. Bladder training and Kegel exercises for women with urinary complaints living in a rest home[J]. Gerontology, 2008, 54(4): 224-231.

[19] FITZGERALD MP, LEMACK G, WHEELER T, et al. Nocturia, nocturnal incontinence prevalence, and response to anticholinergic and behavioral therapy[J]. Int Urogynecol J Pelvic Floor Dysfunct, 2008, 19(11): 1545-1550.

[20] HARDING CK, LAPITAN MC, ARLANDIS S, et al. EAU guidelines on non-neurogenic female lower urinary tract symptoms (limited update march 2026)[M]. Arnhem: European Association of Urology, 2026.

[21] 罗添龙, 黄海. EAU 2024 热点速递:尿控领域研究新进展[J]. 临床泌尿外科杂志, 2024, 39(6): 554-556.

[22] PARSONS JK, KASHEFI C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms[J]. Eur Urol, 2008, 53(6): 1228-1235.

[23] WOLIN KY, GRUBB RLR, PAKPAHAN R, et al. Physical activity and benign prostatic hyperplasia-related outcomes and nocturia[J]. Med Sci Sports Exerc, 2015, 47(3): 581-592.

基金资助

国家重点研发计划项目(2022YFC3602904)

国家重点研发计划项目(2023YFC3606004)

广州临床特色技术项目(2026P-TS004)